中商官网
研究报告
常茂生物（HK0954）
| 科目\年度 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 |
原始货币 |
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| 审计意见 |
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| 报表核心指标 |
-- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| 现金及现金等价物净增加额 |
-- | -3171.80 | 2938.40 | -152.90 | -7481.40 | 1629.70 | 3738.40 | 1264.50 | 2093.80 | -4537.70 | 3568.80 | -571.60 | -4338.80 | 4694.30 |
| 经营活动现金流量净额 |
1951.70 | -3231.70 | -234.90 | 1963.30 | -693.90 | 5890.50 | 11832.70 | 4447.80 | 6578.10 | 4913.20 | 7191.90 | 9616.80 | 6858.40 | 9361.90 |
| 投资活动现金流量净额 |
653.30 | -3253.40 | -12210.60 | -22071.00 | -14462.00 | 714.80 | -3578.60 | -1649.50 | -6035.10 | -2073.70 | -2457.80 | -6569.60 | -5768.40 | -141.90 |
| 融资活动现金流量净额 |
-- | 3313.30 | 15383.90 | 19954.80 | 7674.50 | -4975.60 | -4515.70 | -1533.80 | 1550.80 | -7377.20 | -1165.30 | -3618.80 | -5428.80 | -4525.70 |
| 现金及现金等价物期末余额 |
6815.20 | 5796.30 | 8955.40 | 5999.30 | 5817.80 | 13369.30 | 11931.60 | 8139.80 | 6875.20 | 4781.60 | 9319.10 | 5750.30 | 6319.00 | 10657.80 |
| 经营活动现金流量净额 |
1951.70 | -3231.70 | -234.90 | 1963.30 | -693.90 | 5890.50 | 11832.70 | 4447.80 | 6578.10 | 4913.20 | 7191.90 | 9616.80 | 6858.40 | 9361.90 |
| 折旧与摊销 |
5420.40 | 4413.30 | 4203.90 | 3220.20 | 2921.40 | 3278.30 | 3535.90 | 3437.00 | 3790.60 | 3640.60 | 3674.70 | 3376.70 | 3513.30 | 3677.60 |
| 营运资金变动 |
-- | -1661.30 | -2529.10 | -10096.80 | -1954.20 | 25.00 | 3604.10 | -3762.40 | 3891.00 | -1039.90 | -342.50 | 3606.50 | -3307.70 | 2031.20 |
| 投资活动现金流量净额 |
653.30 | -3253.40 | -12210.60 | -22071.00 | -14462.00 | 714.80 | -3578.60 | -1649.50 | -6035.10 | -2073.70 | -2457.80 | -6569.60 | -5768.40 | -141.90 |
| 资本性支出 |
883.10 | 6396.50 | 13916.90 | 22351.90 | 25121.40 | 7966.90 | 4126.60 | 3290.20 | 4989.20 | 2856.60 | 3057.00 | 6492.50 | 5839.90 | 4211.50 |
| 融资活动现金流量净额 |
-- | 3313.30 | 15383.90 | 19954.80 | 7674.50 | -4975.60 | -4515.70 | -1533.80 | 1550.80 | -7377.20 | -1165.30 | -3618.80 | -5428.80 | -4525.70 |
| 支付股息 |
-- | -- | -4233.20 | -- | -1059.40 | -2913.40 | -2648.50 | -- | -1059.40 | -1377.20 | -1165.30 | -2118.80 | -1483.20 | -1271.30 |
| 现金及现金等价物净增加额 |
-- | -3171.80 | 2938.40 | -152.90 | -7481.40 | 1629.70 | 3738.40 | 1264.50 | 2093.80 | -4537.70 | 3568.80 | -571.60 | -4338.80 | 4694.30 |
| 加：现金及现金等价物期初余额 |
5796.30 | 8955.40 | 5999.30 | 5817.80 | 13369.30 | 11931.60 | 8139.80 | 6875.20 | 4781.60 | 9319.10 | 5750.30 | 6319.00 | 10657.80 | 5963.50 |
| 汇率变动对现金及现金等价物的影响 |
-- | 12.70 | 17.70 | 334.40 | -70.10 | -192.00 | 53.40 | 0.10 | -0.20 | 0.20 | -- | 2.90 | -- | -- |
| 现金及现金等价物期末余额 |
6815.20 | 5796.30 | 8955.40 | 5999.30 | 5817.80 | 13369.30 | 11931.60 | 8139.80 | 6875.20 | 4781.60 | 9319.10 | 5750.30 | 6319.00 | 10657.80 |